Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Cappelli

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Annals of the Rheumatic Diseases|April 5, 2023
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritisAnne R Bass, Noha Abdel-Wahab, Pankti D Reid, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Seminars in Arthritis and Rheumatism|November 13, 2022
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working groupNilasha Ghosh, Nina Couette, Wouter H van Binsbergen, et al.
Seminars in Arthritis and Rheumatism|September 15, 2020
Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping reviewAdam Kilian, Yu Pei Chock, Irvin J Huang, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term dataTessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Journal for Immunotherapy of Cancer|April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapySteven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 4, 2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R Bass, Eliza Chakravarty, Elie A Akl, et al.
Arthritis Care & Research|January 4, 2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R Bass, Eliza Chakravarty, Elie A Akl, et al.
The Journal of Clinical Investigation|October 15, 2024
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Annals of the Rheumatic Diseases|April 5, 2023
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritisAnne R Bass, Noha Abdel-Wahab, Pankti D Reid, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Seminars in Arthritis and Rheumatism|November 13, 2022
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working groupNilasha Ghosh, Nina Couette, Wouter H van Binsbergen, et al.
Seminars in Arthritis and Rheumatism|September 15, 2020
Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping reviewAdam Kilian, Yu Pei Chock, Irvin J Huang, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term dataTessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Journal for Immunotherapy of Cancer|April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapySteven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 4, 2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R Bass, Eliza Chakravarty, Elie A Akl, et al.
Arthritis Care & Research|January 4, 2023
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R Bass, Eliza Chakravarty, Elie A Akl, et al.
The Journal of Clinical Investigation|October 15, 2024
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
Pageof 6